PLANO, Texas, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading medical device contract development and manufacturing organization (CDMO), today announced participation at the Wells Fargo 2024 Healthcare Conference, to be held Sept. 4 – 6, 2024, in Boston. Integer President and Chief Executive Officer Joseph Dziedzic is scheduled to present on Wednesday, Sept. 4, at 2:15 pm EDT.
A live webcast of the presentation will be accessible under “News & Events” on the Investor Relations section of the Integer website at investor.integer.net.
Learn more about Integer at www.integer.net.
About Integer®
Integer Holdings Corporation (NYSE:ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, serving the cardiac rhythm management, neuromodulation, and cardio and vascular markets. As a strategic partner of choice to medical device companies and OEMs, the Company is committed to enhancing the lives of patients worldwide by providing innovative, high-quality products and solutions. The Company's brands include Greatbatch Medical®, Lake Region Medical® and Electrochem®. Additional information is available at www.integer.net.
| Investor Relations: Andrew Senn This email address is being protected from spambots. You need JavaScript enabled to view it. 763.951.8312 | Media Relations: Kelly Butler This email address is being protected from spambots. You need JavaScript enabled to view it. 469.731.6617 |
| Last Trade: | US$132.17 |
| Daily Change: | -0.35 -0.26 |
| Daily Volume: | 109,505 |
| Market Cap: | US$4.430B |
October 24, 2024 September 23, 2024 July 25, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
